Genmab ADR (NASDAQ: GMAB) on Tuesday, plunged -0.82% from the previous trading day, before settling in for the closing price of $20.67. Within the past 52 weeks, GMAB’s price has moved between $20.50 and $32.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 43.21%. The company achieved an average annual earnings per share of 30.18%. With a float of $635.13 million, this company’s outstanding shares have now reached $653.30 million.
Let’s determine the extent of company efficiency that accounts for 2204 employees. In terms of profitability, gross margin is 96.08%, operating margin of 32.33%, and the pretax margin is 32.83%.
Genmab ADR (GMAB) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Genmab ADR is 0.00%, while institutional ownership is 8.28%.
Genmab ADR (GMAB) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.14 earnings per share (EPS) for the period falling under the consensus outlook (set at 0.28) by -0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.96% during the next five years compared to 20.52% growth over the previous five years of trading.
Genmab ADR (NASDAQ: GMAB) Trading Performance Indicators
Genmab ADR (GMAB) is currently performing well based on its current performance indicators. A quick ratio of 5.15 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.53. Likewise, its price to free cash flow for the trailing twelve months is 13.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.04, a number that is poised to hit 0.35 in the next quarter and is forecasted to reach 1.38 in one year’s time.
Technical Analysis of Genmab ADR (GMAB)
Looking closely at Genmab ADR (NASDAQ: GMAB), its last 5-days average volume was 1.75 million, which is a jump from its year-to-date volume of 0.71 million. As of the previous 9 days, the stock’s Stochastic %D was 4.11%. Additionally, its Average True Range was 0.50.
During the past 100 days, Genmab ADR’s (GMAB) raw stochastic average was set at 1.35%, which indicates a significant decrease from 3.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.63% in the past 14 days, which was higher than the 26.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.53, while its 200-day Moving Average is $26.99. However, in the short run, Genmab ADR’s stock first resistance to watch stands at $20.63. Second resistance stands at $20.75. The third major resistance level sits at $20.87. If the price goes on to break the first support level at $20.38, it is likely to go to the next support level at $20.26. Now, if the price goes above the second support level, the third support stands at $20.14.
Genmab ADR (NASDAQ: GMAB) Key Stats
Market capitalization of the company is 13.02 billion based on 661,768K outstanding shares. Right now, sales total 2,392 M and income totals 631,910 K. The company made 816,600 K in profit during its latest quarter, and 186,610 K in sales during its previous quarter.
